G3BP1 interacts with YWHAZ to regulate chemoresistance and predict adjuvant chemotherapy benefit in gastric cancer
暂无分享,去创建一个
Jian-ping Guo | Yuanyuan Ruan | Xuefei Wang | Yihong Sun | Zhaoqing Tang | Junjie Zhao | Haojie Li | L. Min | Liyu Huang | Xu-hong Fu | Hao Chen | Jie Sun | Jingyi Yin
[1] Li Jiang,et al. Stress granule: A promising target for cancer treatment , 2019, British journal of pharmacology.
[2] F. Veith,et al. Why randomized controlled trials do not always reflect reality. , 2019, Journal of vascular surgery.
[3] W. Xue,et al. G3BP1 promotes DNA binding and activation of cGAS , 2018, Nature Immunology.
[4] Herbert Yu,et al. A G3BP1-Interacting lncRNA Promotes Ferroptosis and Apoptosis in Cancer via Nuclear Sequestration of p53. , 2018, Cancer research.
[5] João Pedro de Magalhães,et al. Gene co-expression analysis for functional classification and gene–disease predictions , 2017, Briefings Bioinform..
[6] Quan P. Ly,et al. Gastric Cancer, Version 3.2016; Clinical Practice Guidelines in Oncology , 2016 .
[7] Jin-bo Gao,et al. Molecular mechanisms of chemoresistance in gastric cancer , 2016, World journal of gastrointestinal oncology.
[8] Shufeng Zhou,et al. Molecular mechanisms for tumour resistance to chemotherapy , 2016, Clinical and experimental pharmacology & physiology.
[9] K. Pilancı,et al. Current adjuvant treatment modalities for gastric cancer: From history to the future. , 2016, World journal of gastrointestinal oncology.
[10] Quan P. Ly,et al. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[11] F. Roviello,et al. Surgical management of advanced gastric cancer: An evolving issue. , 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[12] Yuanyuan Ruan,et al. Overexpression of Ras‐GTPase‐activating protein SH3 domain‐binding protein 1 correlates with poor prognosis in gastric cancer patients , 2015, Histopathology.
[13] D. Shin,et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.
[14] A. Bode,et al. Resveratrol induces apoptosis by directly targeting Ras-GTPase activating protein SH3 domain binding protein 1 (G3BP1) , 2014, Oncogene.
[15] L. Galluzzi,et al. Systems biology of cisplatin resistance: past, present and future , 2014, Cell Death and Disease.
[16] Wenlin Xu,et al. Relationship between P53 Status and Response to Chemotherapy in Patients with Gastric Cancer: A Meta-Analysis , 2014, PloS one.
[17] H. Chun,et al. Chemotherapy for Advanced Gastric Cancer: Review and Update of Current Practices , 2013, Gut and liver.
[18] H. Tsuda,et al. Overexpression of YWHAZ relates to tumor cell proliferation and malignant outcome of gastric carcinoma , 2013, British Journal of Cancer.
[19] M. Higuchi,et al. Stress Granules Inhibit Apoptosis by Reducing Reactive Oxygen Species Production , 2012, Molecular and Cellular Biology.
[20] L. Varışlı. Meta-analysis of the expression of the mitosis-related gene Fam83D. , 2012, Oncology letters.
[21] L. Galluzzi,et al. Molecular mechanisms of cisplatin resistance , 2012, Oncogene.
[22] Inkyung Jung,et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. , 2012, European journal of cancer.
[23] L. Jacks,et al. Comparison of Gastric Cancer Survival Following R0 Resection in the United States and Korea Using an Internationally Validated Nomogram , 2010, Annals of surgery.
[24] R. Parker,et al. Eukaryotic stress granules: the ins and outs of translation. , 2009, Molecular cell.
[25] C. Reynolds,et al. Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy , 2009, Clinical Cancer Research.
[26] Yasuo Ohashi,et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.
[27] Mihee M. Kim,et al. Modulation of p53 and MDM2 activity by novel interaction with Ras-GAP binding proteins (G3BP) , 2007, Oncogene.
[28] Elisabeth Brambilla,et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. , 2006, The New England journal of medicine.
[29] C. V. D. van de Velde,et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.
[30] J. Tazi,et al. Control of Fetal Growth and Neonatal Survival by the RasGAP-Associated Endoribonuclease G3BP , 2005, Molecular and Cellular Biology.
[31] M. Raderer,et al. Palliative chemotherapy for advanced gastric cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] W. Sadee,et al. Growth factor signaling and resistance to cancer chemotherapy. , 2004, Current topics in medicinal chemistry.
[33] Fuminori Tsuruta,et al. JNK promotes Bax translocation to mitochondria through phosphorylation of 14‐3‐3 proteins , 2004, The EMBO journal.
[34] P. Johnston,et al. 5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.
[35] K. Chébli,et al. The RasGAP-associated endoribonuclease G3BP assembles stress granules , 2003, The Journal of cell biology.
[36] Masashi Narita,et al. 14-3-3 Interacts Directly with and Negatively Regulates Pro-apoptotic Bax* , 2003, The Journal of Biological Chemistry.
[37] Scott W. Lowe,et al. Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.
[38] J. Tazi,et al. RasGAP-Associated Endoribonuclease G3BP: Selective RNA Degradation and Phosphorylation-Dependent Localization , 2001, Molecular and Cellular Biology.
[39] Scott A. Hundahl,et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.
[40] L. Debussche,et al. A Ras-GTPase-activating protein SH3-domain-binding protein , 1996, Molecular and cellular biology.